Investigación: Retatrutide

Triple agonist (GLP-1/GIP/Glucagon) — next-gen weight loss

Retatrutide
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
N Engl J Med 2023 450 Clinical Trial
Phase 2 trial of retatrutide (GLP-1/GIP/glucagon triple agonist) in adults with obesity demonstrated dose-dependent weight loss and acceptable safety profile.